Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Carcinoma, Hepatocellular 15Small Cell Lung Carcinoma 11Triple Negative Breast Neoplasms 9Neoplasms 8Colorectal Neoplasms 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Lung Neoplasms 5Carcinoma, Renal Cell 5Ovarian Neoplasms 4Carcinoma, Transitional Cell 3Carcinoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Melanoma 2Colonic Neoplasms 2Venous Thrombosis 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Rectal Neoplasms 1Radiation Pneumonitis 1Prostatic Neoplasms, Castration-Resistant 1Peritoneal Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Non-Small-Cell Lung 1

Interventions

Etoposide 3Cisplatin 2Carboplatin 2belotecan 1atezolizumab 1RRx-001 1PM 01183 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Small Cell × atezolizumab × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡